Aeterna Zentaris snags $69M pact on perifosine

Canada's Aeterna Zentaris will pocket $8.3 million upfront from Yakult Honsha, which is licensing the Japanese rights to Aeterna's lead cancer drug, perifosine. Aeterna is also in line for up to $60.9 million in milestones. Perifosine is an oral PI3K/Akt inhibitor currently in two Phase III programs for the treatment of colorectal cancer and multiple myeloma in the United States and Europe. Aeterna release